{"id":302395,"date":"2025-11-22T23:42:12","date_gmt":"2025-11-22T23:42:12","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/302395\/"},"modified":"2025-11-22T23:42:12","modified_gmt":"2025-11-22T23:42:12","slug":"asah1-mediated-sphingolipid-metabolic-reprogramming-in-venetoclax-resistance-of-aml-beyond-the-monocytic-phenotypes-bmc-cancer","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/302395\/","title":{"rendered":"ASAH1-mediated sphingolipid metabolic reprogramming in venetoclax resistance of AML: beyond the monocytic phenotypes | BMC Cancer"},"content":{"rendered":"

Lagadinou ED, Sach A, Callahan K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12:329\u201341. https:\/\/doi.org\/10.1016\/j.stem.2012.12.013<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4:362\u201375. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0609<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2012971<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6:1106\u201317. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0313<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Sullivan GP, Flanagan L, Rodrigues DA, N\u00ed Chonghaile T. The path to venetoclax resistance is paved with mutations, metabolism, and more. Sci Transl Med. 2022;14:eabo6891. https:\/\/doi.org\/10.1126\/scitranslmed.abo6891<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Stevens BM, Jones CL, Pollyea DA, et al. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nat Cancer. 2020;1(12):1176\u201387. https:\/\/doi.org\/10.1038\/s43018-020-00126-z<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Zhang H, Nakauchi Y, K\u00f6hnke T, et al. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat Cancer. 2020;1:826\u201339. https:\/\/doi.org\/10.1038\/s43018-020-0103-x<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Kuusanm\u00e4ki H, Dufva O, V\u00e4h\u00e4-Koskela M, et al. Erythroid\/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia. Blood. 2023;141:1610\u201325. https:\/\/doi.org\/10.1182\/blood.2021011094<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Zeng AGX, Bansal S, Jin L, et al. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nat Med. 2022;28:1212\u201323. https:\/\/doi.org\/10.1038\/s41591-022-01819-x<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Kurtz SE, Eide CA, Kaempf A, et al. Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia. Blood Adv. 2022;6:3062\u20137. https:\/\/doi.org\/10.1182\/bloodadvances.2021006307<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Kuusanm\u00e4ki H, Lepp\u00e4 A-M, P\u00f6l\u00f6nen P, et al. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica. 2020;105:708\u201320. https:\/\/doi.org\/10.3324\/haematol.2018.214882<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Pei S, Pollyea DA, Gustafson A, et al. Monocytic subclones confer resistance to Venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020;10:536\u201351. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0710<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Zong L, Yin M, Kong J, et al. Development of a scoring system for predicting primary resistance to venetoclax plus hypomethylating agents (HMAs) in acute myeloid leukemia patients. Mol Carcinog. 2023;62:1572\u201384. https:\/\/doi.org\/10.1002\/mc.23600<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Zhao L, Yang J, Chen M, et al. Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study. Ann Hematol. 2024;103:1197\u2013209. https:\/\/doi.org\/10.1007\/s00277-024-05646-7<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Pei S, Shelton IT, Gillen AE, et al. A novel type of monocytic leukemia stem cell revealed by the clinical use of Venetoclax-based therapy. Cancer Discov. 2023;13:2032\u201349. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-1297<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Lachowiez CA, Loghavi S, Zeng Z, et al. A phase Ib\/II study of Ivosidenib with Venetoclax\u2009\u00b1\u2009Azacitidine in IDH1-mutated myeloid malignancies. Blood Cancer Discov. 2023;4:276\u201393. https:\/\/doi.org\/10.1158\/2643-3230.BCD-22-0205<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Ito K, Suda T. Metabolic requirements for the maintenance of self-renewing stem cells. Nat Rev Mol Cell Biol. 2014;15:243\u201356. https:\/\/doi.org\/10.1038\/nrm3772<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;9:139\u201350. https:\/\/doi.org\/10.1038\/nrm2329<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Ung J, Tan S-F, Fox TE, et al. Harnessing the power of sphingolipids: prospects for acute myeloid leukemia. Blood Rev. 2022;55:100950. https:\/\/doi.org\/10.1016\/j.blre.2022.100950<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Tan S-F, Liu X, Fox TE, et al. Acid ceramidase is upregulated in AML and represents a novel therapeutic target. Oncotarget. 2016;7:83208\u201322. https:\/\/doi.org\/10.18632\/oncotarget.13079<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Xie SZ, Garcia-Prat L, Voisin V, et al. Sphingolipid modulation activates proteostasis programs to govern human hematopoietic stem cell Self-Renewal. Cell Stem Cell. 2019;25:639\u2013e6537. https:\/\/doi.org\/10.1016\/j.stem.2019.09.008<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Bottomly D, Long N, Schultz AR, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022;40:850\u2013e8649. https:\/\/doi.org\/10.1016\/j.ccell.2022.07.002<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Roh J, Pak H-K, Jeong S, et al. The comprehensive expression of BCL2 family genes determines the prognosis of diffuse large B-cell lymphoma. Biochem Biophys Res Commun. 2023;673:36\u201343. https:\/\/doi.org\/10.1016\/j.bbrc.2023.06.061<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Cancer Genome Atlas Research Network, Ley TJ, Miller C, et al. Genomic and epigenomic landscapes of adult de Novo acute myeloid leukemia. N Engl J Med. 2013;368:2059\u201374. https:\/\/doi.org\/10.1056\/NEJMoa1301689<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

McNeer NA, Philip J, Geiger H, et al. Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. Leukemia. 2019;33:1934\u201343. https:\/\/doi.org\/10.1038\/s41375-019-0402-3<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Leek JT, Johnson WE, Parker HS, et al. The Sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012;28:882\u20133. https:\/\/doi.org\/10.1093\/bioinformatics\/bts034<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Liu Z, Liu L, Weng S, et al. Machine learning-based integration develops an immune-derived LncRNA signature for improving outcomes in colorectal cancer. Nat Commun. 2022;13:816. https:\/\/doi.org\/10.1038\/s41467-022-28421-6<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559. https:\/\/doi.org\/10.1186\/1471-2105-9-559<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Yoon S-H, Choi S-W, Nam SW, et al. Preoperative immune landscape predisposes adverse outcomes in hepatocellular carcinoma patients with liver transplantation. NPJ Precis Oncol. 2021;5:27. https:\/\/doi.org\/10.1038\/s41698-021-00167-2<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Wu T, Hu E, Xu S, et al. Clusterprofiler 4.0: a universal enrichment tool for interpreting omics data. Innovation (Camb). 2021;2:100141. https:\/\/doi.org\/10.1016\/j.xinn.2021.100141<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Bosc C, Saland E, Bousard A, et al. Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia. Nat Cancer. 2021;2:1204\u201323. https:\/\/doi.org\/10.1038\/s43018-021-00264-y<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Lasry A, Nadorp B, Fornerod M, et al. An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. Nat Cancer. 2023;4:27\u201342. https:\/\/doi.org\/10.1038\/s43018-022-00480-0<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Korsunsky I, Millard N, Fan J, et al. Fast, sensitive and accurate integration of single-cell data with harmony. Nat Methods. 2019;16:1289\u201396. https:\/\/doi.org\/10.1038\/s41592-019-0619-0<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

van Galen P, Hovestadt V, Wadsworth Ii MH, et al. Single-Cell RNA-Seq reveals AML hierarchies relevant to disease progression and immunity. Cell. 2019;176:1265\u2013e128124. https:\/\/doi.org\/10.1016\/j.cell.2019.01.031<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Gulati GS, Sikandar SS, Wesche DJ, et al. Single-cell transcriptional diversity is a hallmark of developmental potential. Science. 2020;367:405\u201311. https:\/\/doi.org\/10.1126\/science.aax0249<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Aibar S, Gonz\u00e1lez-Blas CB, Moerman T, et al. SCENIC: single-cell regulatory network inference and clustering. Nat Methods. 2017;14:1083\u20136. https:\/\/doi.org\/10.1038\/nmeth.4463<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Li Y, Sung Y, Choi YE, et al. Synergistic enhancement of antitumor effects by combining abemaciclib with desipramine. Int J Mol Sci. 2024;25:7407. https:\/\/doi.org\/10.3390\/ijms25137407<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Jones CL, Stevens BM, Pollyea DA, et al. Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells. Cell Stem Cell. 2020;27:748\u2013e7644. https:\/\/doi.org\/10.1016\/j.stem.2020.07.021<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7\u201317. https:\/\/doi.org\/10.1182\/blood-2018-08-868752<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Jones CL, Inguva A, Jordan CT. Targeting energy metabolism in cancer stem cells: progress and challenges in leukemia and solid tumors. Cell Stem Cell. 2021;28:378\u201393. https:\/\/doi.org\/10.1016\/j.stem.2021.02.013<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Mishra SK, Millman SE, Zhang L. Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets. Blood. 2023;141:1119\u201335. https:\/\/doi.org\/10.1182\/blood.2022018092<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Zhai Y, Shen H, Wei H. A comprehensive metabolism-related gene signature predicts the survival of patients with acute myeloid leukemia. Genes. 2023;15:63. https:\/\/doi.org\/10.3390\/genes15010063<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Ren N, Wang J, Li R, et al. Prognostic implications of metabolism-related genes in acute myeloid leukemia. Front Genet. 2024;15:1424365. https:\/\/doi.org\/10.3389\/fgene.2024.1424365<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Qin H, Peng M, Cheng J, et al. A novel LGALS1-depended and immune-associated fatty acid metabolism risk model in acute myeloid leukemia stem cells. Cell Death Dis. 2024;15:482. https:\/\/doi.org\/10.1038\/s41419-024-06865-6<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Lo Presti C, Fauvelle F, Jacob M-C, et al. The metabolic reprogramming in acute myeloid leukemia patients depends on their genotype and is a prognostic marker. Blood Adv. 2021;5:156\u201366. https:\/\/doi.org\/10.1182\/bloodadvances.2020002981<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Lewis AC, Wallington-Beddoe CT, Powell JA, Pitson SM. Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies. Cell Death Discov. 2018;4:72. https:\/\/doi.org\/10.1038\/s41420-018-0075-0<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Tan S-F, Pearson JM, Feith DJ, Loughran TP. The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia. Expert Opin Ther Targets. 2017;21:583\u201390. https:\/\/doi.org\/10.1080\/14728222.2017.1322065<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Lewis AC, Pope VS, Tea MN, et al. Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia. Blood. 2022;139:3737\u201351. https:\/\/doi.org\/10.1182\/blood.2021013277<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Kao L-P, Morad SAF, Davis TS, et al. Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells. J Lipid Res. 2019;60:1590\u2013602. https:\/\/doi.org\/10.1194\/jlr.RA119000251<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Ricci C, Onida F, Ghidoni R. Sphingolipid players in the leukemia arena. Biochim Biophys Acta. 2006;1758:2121\u201332. https:\/\/doi.org\/10.1016\/j.bbamem.2006.06.016<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Khokhlatchev AV, Sharma A, Deering TG, et al. Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia. FASEB J. 2022;36:e22514. https:\/\/doi.org\/10.1096\/fj.202200765R<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Hannun YA, Obeid LM. Sphingolipids and their metabolism in physiology and disease. Nat Rev Mol Cell Biol. 2018;19:175\u201391. https:\/\/doi.org\/10.1038\/nrm.2017.107<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Tan S-F, Dunton W, Liu X, et al. Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-\u03baB-dependent P-glycoprotein upregulation. J Lipid Res. 2019;60:1078\u201386. https:\/\/doi.org\/10.1194\/jlr.M091876<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Pearson JM, Tan S-F, Sharma A, et al. Ceramide analog SACLAC modulates sphingolipid levels and Mcl-1 splicing to induce apoptosis in acute myeloid leukemia. Mol Cancer Res. 2020;18:352\u201363. https:\/\/doi.org\/10.1158\/1541-7786.MCR-19-0619<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Casson L, Howell L, Mathews LA, et al. Inhibition of ceramide metabolism sensitizes human leukemia cells to Inhibition of BCL2-like proteins. PLoS ONE. 2013;8:e54525. https:\/\/doi.org\/10.1371\/journal.pone.0054525<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Siskind LJ, Feinstein L, Yu T, et al. Anti-apoptotic Bcl-2 family proteins disassemble ceramide channels. J Biol Chem. 2008;283:6622\u201330. https:\/\/doi.org\/10.1074\/jbc.M706115200<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Zhang T, Barclay L, Walensky LD, Saghatelian A. Regulation of mitochondrial ceramide distribution by members of the BCL-2 family. J Lipid Res. 2015;56:1501\u201310. https:\/\/doi.org\/10.1194\/jlr.M058750<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Chipuk JE, McStay GP, Bharti A, et al. Sphingolipid metabolism cooperates with BAK and BAX to promote the mitochondrial pathway of apoptosis. Cell. 2012;148:988\u20131000. https:\/\/doi.org\/10.1016\/j.cell.2012.01.038<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Anderson MA, Deng J, Seymour JF, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016;127:3215\u201324. https:\/\/doi.org\/10.1182\/blood-2016-01-688796<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Hern\u00e1ndez-Corbacho MJ, Salama MF, Canals D, et al. Sphingolipids in mitochondria. Biochimica et biophysica acta (BBA) -. Mol Cell Biology Lipids. 2017;1862:56\u201368. https:\/\/doi.org\/10.1016\/j.bbalip.2016.09.019<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Pyne S, Adams DR, Pyne NJ. Sphingosine 1-phosphate and sphingosine kinases in health and disease: recent advances. Prog Lipid Res. 2016;62:93\u2013106. https:\/\/doi.org\/10.1016\/j.plipres.2016.03.001<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Sango J, Carcamo S, Sirenko M, et al. RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax. Nature. 2024;636:241\u201350. https:\/\/doi.org\/10.1038\/s41586-024-08137-x<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Wang Q, Zhang N, Liu L, et al. Comprehensive analysis of clinical prognostic features and tumor microenvironment landscape of CD11b\u2009+\u2009CD64\u2009+\u2009patients with acute myeloid leukemia. Cell Oncol. 2023;46:1253\u201368. https:\/\/doi.org\/10.1007\/s13402-023-00808-7<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Waclawiczek A, Lepp\u00e4 A-M, Renders S, et al. Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to Azacitidine\/Venetoclax. Cancer Discov. 2023;13:1408\u201327. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0939<\/a>.<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n","protected":false},"excerpt":{"rendered":"Lagadinou ED, Sach A, Callahan K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human…\n","protected":false},"author":2,"featured_media":301069,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[172695,64,63,5562,5563,86763,1325,137,92009,7407,172697,5311,172694,104526,172696],"class_list":["post-302395","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-acute-myeloid-leukemia","tag-au","tag-australia","tag-biomedicine","tag-cancer-research","tag-drug-resistance","tag-general","tag-health","tag-health-promotion-and-disease-prevention","tag-medicine-public-health","tag-monocytic","tag-oncology","tag-sphingolipid","tag-surgical-oncology","tag-venetoclax"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/302395","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=302395"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/302395\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/301069"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=302395"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=302395"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=302395"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}